The abstract is read at the publisher; the summary is JClub's.
Beta-blockers remain foundational cardiovascular therapy, but newer randomized trials and large population analyses show their benefits are more nuanced and must be individualized.
- Why it matters: Prior guidance assumed routine use across many cardiovascular scenarios, yet recent evidence has questioned appropriateness in several common settings.
- What they did: This review synthesizes established indications (including chronic heart failure with reduced ejection fraction and angina) and evaluates newer studies addressing myocardial infarction with preserved ejection fraction, stable coronary artery disease, heart failure with preserved ejection fraction, first-line hypertension, and perioperative management.
- The result: The evidence supports an indication-focused framework tied to underlying pathology, ventricular function, and symptom burden, while highlighting where additional research is needed to improve prescribing and deprescribing.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.